title: The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex.
abstract: Psychostimulants are highly effective in the treatment of attention-deficit/hyperactivity disorder. The clinical efficacy of these drugs is strongly linked to their ability to improve cognition dependent on the prefrontal cortex (PFC) and extended frontostriatal circuit. The procognitive actions of psychostimulants are only associated with low doses. Surprisingly, despite nearly 80 years of clinical use, the neurobiology of the procognitive actions of psychostimulants has only recently been systematically investigated. Findings from this research unambiguously demonstrate that the cognition-enhancing effects of psychostimulants involve the preferential elevation of catecholamines in the PFC and the subsequent activation of norepinephrine α2 and dopamine D1 receptors. In contrast, while the striatum is a critical participant in PFC-dependent cognition, where examined, psychostimulant action within the striatum is not sufficient to enhance cognition. At doses that moderately exceed the clinical range, psychostimulants appear to improve PFC-dependent attentional processes at the expense of other PFC-dependent processes (e.g., working memory, response inhibition). This differential modulation of PFC-dependent processes across dose appears to be associated with the differential involvement of noradrenergic α2 versus α1 receptors. Collectively, this evidence indicates that at low, clinically relevant doses, psychostimulants are devoid of the behavioral and neurochemical actions that define this class of drugs and instead act largely as cognitive enhancers (improving PFC-dependent function). This information has potentially important clinical implications as well as relevance for public health policy regarding the widespread clinical use of psychostimulants and for the development of novel pharmacologic treatments for attention-deficit/hyperactivity disorder and other conditions associated with PFC dysregulation.
authors.affiliation: Department of Psychology, University of Wisconsin, Madison, Wisconsin.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Spencer
authors.affiliation: Department of Psychology, University of Wisconsin, Madison, Wisconsin.
authors.forename: David M
authors.initials: DM
authors.lastname: Devilbiss
authors.affiliation: Department of Psychology, University of Wisconsin, Madison, Wisconsin. Electronic address: berridge@wisc.edu.
authors.forename: Craig W
authors.initials: CW
authors.lastname: Berridge
mesh_terms: D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects*; D006801:Humans; D017397:Prefrontal Cortex / Q000187:drug effects*
chemical_list: D000697:Central Nervous System Stimulants
keywords: ADHD; Cognition; Dopamine; Norepinephrine; Prefrontal cortex; Stimulants